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Abstract
Objective—Although antiretroviral treatment (ART) has reduced the incidence of HIV-related 
opportunistic infections among children living with HIV, access to ART remains limited for 
children, especially in resource-limited settings. This paper reviews current knowledge on the 
contribution of opportunistic infections and common childhood illnesses to morbidity and 
mortality in children living with HIV, highlights interventions known to improve the health of 
children, and identifies research gaps for further exploration.
Design and Methods—Literature review of peer-reviewed articles and abstracts combined with 
expert opinion and operational experience.
Results—Morbidity and mortality due to opportunistic infections has decreased in both 
developed and resource-limited countries. However, the burden of HIV-related infections remains 
high, especially in sub-Saharan Africa, where the majority of HIV-infected children live. 
Limitations in diagnostic capacity in resource-limited settings have resulted in a relative paucity of 
data on opportunistic infections in children. Additionally, the reliance on clinical diagnosis means 
that opportunistic infections are often confused with common childhood illnesses which also 
contribute to excess morbidity and mortality in these children. Although several preventive 
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interventions have been shown to decrease opportunistic infection-related mortality, 
implementation of many of these interventions remains inconsistent.
Conclusions—In order to reduce opportunistic infection-related mortality, early ART must be 
expanded, training for front-line clinicians must be improved, and additional research is needed to 
improve screening and diagnostic algorithms.
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Introduction
Despite substantial global progress toward reducing new pediatric HIV infections, there 
were approximately 3.4 million children living with HIV and 230 000 AIDS-related deaths 
among children in 2011 [1]. More than 90% of HIV-infected children live in sub-Saharan 
Africa, meaning that this region is also disproportionately affected by pediatric HIV-related 
mortality [2]. Pooled analyses of data from sub-Saharan Africa show that more than half of 
HIV-infected infants die by age 2 years without antiretroviral treatment (ART), compared 
with 8% of HIV-exposed uninfected infants [3,4]. Even with ART, mortality rates in HIV-
infected children are estimated to be at least 30 times higher than mortality rates among 
HIV-unexposed children, largely due to the impact of opportunistic infections and an 
increased susceptibility to common childhood illnesses such as diarrhea, pneumonia, 
malaria, and malnutrition [5–8]. Opportunistic infections are frequently the presenting 
symptom of HIV among children with undiagnosed infection or may be the determining 
factor for initiation of ART in known HIV-infected children who do not meet other criteria 
for treatment. As with adults, ART remains the single most effective intervention for 
reducing the incidence of opportunistic infections, decreasing opportunistic infection-related 
morbidity, and improving survival of HIV-infected patients [5,6,9,10]. Since the widespread 
introduction of ART in sub-Saharan Africa beginning in 2004, HIV-related mortality in 
children has decreased by more than 25% [1,6]. However, access to ART remains limited 
for children living with HIV. In the 22 high HIV burden countries identified as priorities in 
the ‘Global Plan Towards the Elimination of New HIV Infections among Children and 
Keeping their Mothers Alive’ only 34%of children in need of ART received treatment in 
2012 compared with 63% of all people living with HIV (PLHIV), and HIV-infected children 
continue to suffer from disproportionately high rates of morbidity and mortality [11–13]. 
This paper reviews current knowledge on the contribution of opportunistic infections and 
common childhood illnesses to morbidity and mortality in children living with HIV, 
highlights interventions known to improve the health of children, and identifies research 
gaps for further exploration.
Opportunistic infection-related mortality among children living with HIV in 
the United States and Europe
The majority of data on the impact of opportunistic infections in children living with HIV 
come from cohort studies conducted as part of clinical trials in the United States and Europe. 
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The Pediatric AIDS Clinical Trials Group (PACTG) and the Perinatal AIDS Collaborative 
Transmission Study (PACTS) have followed HIV-infected children in the United States 
since the mid-1980s [5,6,9,14–16]. Data from both PACTG and PACTS since 1997 show 
decreases in overall mortality and in opportunistic infection-related mortality for children 
following the introduction of ART. Overall mortality for children in both cohorts declined to 
0.8 deaths per 100 person-years in the post-ART era from pre-ART rates of 7.2 and 18 
deaths per 100 person-years in the PACTG and PACTS cohorts, respectively [5,9,16]. 
Similarly, data from a cohort of children in the United Kingdom and Ireland showed a 
decrease in overall mortality from 8.2 deaths per 100 person-years before 1997 to 0.6 per 
100 person-years by 2006 [17]. The proportion of deaths due to opportunistic infections has 
decreased dramatically with the advent of ART, but these infections remain substantial 
contributors to mortality. In the PACTS cohort, 31.8% of deaths prior to 1991 when ART 
was not widely available were due to opportunistic infections, decreasing to 16.9% in years 
of monotherapy and dual therapy (1991–1996) and to 9.1% when combination therapy was 
available (1997–2004) [16]. Opportunistic infections accounted for 24% of all deaths in 
children in the PACTG cohort between 2001 and 2006 [5]. The most commonly occurring 
infections among HIV-infected children in the developed world include bacterial 
pneumonia, herpes zoster, dermatophyte infections, and oral candidiasis [6]. The 
opportunistic infections causing death have changed since the introduction of ART in the 
United States. The proportion of deaths due to Mycobacterium avium complex (MAC) and 
cryptosporidium have significantly decreased, whereas mortality due to other opportunistic 
infections such as Pneumocystis jirovecii pneumonia (PCP) and cytomegalovirus (CMV) 
remained relatively stable [5,18]. Data from other studies in the United States and other 
developed countries have largely corroborated the PACTG and PACTS data and have 
shown that opportunistic infection-related mortality has declined, but that HIV-related 
infections still remain an important cause of morbidity and mortality in children [14,15, 18–
23].
Opportunistic infections among children living with HIV in resource-limited 
settings
There is a relative paucity of data on the burden of opportunistic infections in children living 
with HIV in resource-limited settings. There are few large published multicountry cohort 
studies specifically designed to measure the incidence of a broad range of opportunistic 
infections in HIV-infected children or determine specific causes of death in resource-limited 
settings where autopsies are not commonly performed. However, the data that are available 
suggest that ART has had a similar impact on decreasing opportunistic infection-related 
morbidity and mortality in resource-limited settings. Data from Thailand show that 
opportunistic infection-related mortality in children decreased from 27% of all causes of 
mortality in the pre-ART era (1989–2002) to 5.7% in the post-ART era (2003–2009). As 
seen in the United States and Europe, the types of opportunistic infections conferring higher 
morbidity (i.e., leading to hospitalization) have changed with the widespread availability of 
ART, although the specific trends were different in Thailand, where the incidence of PCP 
and recurrent salmonella septicemia decreased, whereas mycobacterial and systemic fungal 
infections increased [10]. A recent study demonstrated that the incidence of WHO stage 3 or 
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4 conditions among HIV-infected adults and children in resource-limited settings in Asia 
and Africa was approximately 14 times as high as among patients in a European cohort in 
the first 3 months after ART initiation, although overall incidence of these conditions 
decreased by more than 90% at the end of 12 months following ART initiation [24].
Even where ART is available, HIV-infected children in resource-limited settings continue to 
experience high levels of morbidity and mortality from opportunistic infections. A recent 
study from Latin America that compared a cohort of children with a similar length of 
follow-up, ART utilization, and CD4% at enrollment as the children in the PACTG study 
cohort showed a similar spectrum of opportunistic infections, but a much higher overall 
incidence of opportunistic infections than the children in the United States [25]. A 
systematic review of mortality in resource-limited settings in the ART era found that 
pediatric mortality remains significantly higher than developed countries despite more wide-
spread ART availability, with 8 deaths per 100-child years compared with approximately 
0.8–0.9 deaths per 100 child-years in developed countries [5,26]. This review also 
highlighted the delays in initiation of ART for children in resource-limited settings as 
evidenced by the relatively low CD4+ cell count, low weight-for-age z-scores, and high viral 
loads compared with children in developed countries [26]. Routine program data on HIV-
infected adults and children from 10 countries in Asia and Africa further indicate that the 
highest regional burden of opportunistic infections occurs in Africa, where the incidence of 
any WHO stage 3 condition was three times as high as in Asia, and with pulmonary 
tuberculosis (TB) being the most commonly reported condition [24].
Common childhood illnesses among children living with HIV
In addition to opportunistic infections, HIV-infected children also suffer from diseases 
common in HIV-unexposed children in these settings, including malaria, pneumonia, and 
diarrheal illnesses. A review of hospital admission data in Soweto, South Africa shows that 
pneumonia, diarrhea, and malnutrition were the most common causes of childhood 
hospitalization, especially in HIV-infected children prior to the availability of ART [27]. A 
more recent study from the Democratic Republic of Congo reported that the most common 
causes of death in children on ART included septic shock and diarrhea, which only cause 
8% of deaths in HIV-infected children in the United States [6,28]. The higher incidence of 
diarrhea and diarrhea-related mortality among children living with HIV may be explained by 
an underlying immunocompromised state, comorbid infections, and/or malnutrition, which 
often result from delayed ART initiation [28–30]. Persistent diarrhea, in particular, is 
associated with a high risk of mortality in HIV-infected children. Restoration of immune 
function with ART is a critical component of prevention and treatment of diarrhea in 
children with HIV infection, yet access to ART remains limited, especially in sub-Saharan 
Africa [12,31].
Data from Botswana showed that the burden of respiratory disease among children living 
with HIV is particularly high, causing 83% of deaths among HIV-infected children 
compared to 27–42% in the United States [14,18,32]. Pneumonia was the most common 
serious bacterial illness among HIV-infected children admitted to a hospital in Cape Town, 
South Africa, with common causes including Streptococcus pneumoniae, Staphylococcus 
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aureus, and Klebsiella pneumoniae [33]. Similarly, a study in Thailand showed that the most 
frequent cause of hospital admission among children receiving ART was pneumonia and 
other bacterial infections, accounting for 62% of the admissions [34]. A systematic review 
of the causes of severe pneumonia in HIV-infected children in both resource-limited and 
developed countries found limited data, especially after the availability of ART. The 
available data suggest that PCP and CMV were the most common and second most common 
causes, respectively, of pneumonia in HIV-infected children; additionally, Mycobacterium 
tuberculosis was documented in 8% of children with acute pneumonia in South Africa [35]. 
The limited capacity to diagnose specific infections, such as PCP, CMV, and TB, among 
children in resource-limited settings means that these are often not differentiated from other 
common causes of respiratory disease in HIV-uninfected children [36,37]. Given these 
limitations, the true prevalence of these specific infections among HIV-infected children, 
stratified by ART exposure and CD4 cell count, remains unknown. A recent report showed 
that nearly 30% of the pneumonia burden in sub-Saharan Africa can be attributed to HIV-
related immunosuppression (personal communication, WHO). Although common childhood 
illnesses contribute substantially to morbidity and mortality among children living with 
HIV, the relative burden of opportunistic infections may be underestimated in resource-
limited settings due to limited diagnostic capacity and lack of routine surveillance for these 
illnesses.
Recommendations for prevention of opportunistic infections and common 
childhood illnesses among children living with HIV
Several medical interventions have been proven to reduce morbidity and mortality from 
opportunistic infections and are recommended as prophylactic therapy for children living 
with HIV. Cotrimoxazole has been shown to dramatically reduce the risk of opportunistic 
infections such as PCP and toxoplasmosis and to provide protection against common 
diseases such as malaria [38,39]. Since 2006, WHO has recommended cotrimoxazole 
preventive therapy for all HIV-exposed infants through the end of the breastfeeding period 
and for all HIV-infected infants and children under the age of 5 years [39]. To prevent TB-
related morbidity and mortality in HIV-infected children, WHO recommends isoniazid 
preventive therapy (IPT) for all HIV-infected infants and children with a history of contact 
with a known TB case and for all HIV-infected children over age 12 months who are 
unlikely to have active TB or who have successfully completed treatment for TB disease 
[40–42]. WHO does not recommend the use of fluconazole for primary prophylaxis of 
cryptococcal infection in children and adolescents because available data suggest a lower 
incidence in these age groups [39].
Despite the known benefits and long-standing recommendations for cotrimoxazole and IPT, 
uptake of these interventions remains inconsistent. There are encouraging data from a recent 
national retrospective cohort study in Kenya, which show that 94% of HIV-infected children 
received cotrimoxazole prophylaxis at their last HIV clinic visit between 2004 and 2010 
(unpublished data, CDC). However, data from a South African study showed that a third of 
HIV-exposed children attending a primary healthcare facility did not receive cotrimoxazole 
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[43]. No published global data are available on routine uptake of IPT among HIV-infected 
children.
Further research is needed on the optimal use and duration of opportunistic infection 
prophylaxis regimens for HIV-exposed and HIV-infected children. Recent data confirm the 
benefit of extended cotrimoxazole prophylaxis for HIV-infected children receiving ART in 
resource-limited settings, with ongoing reductions in hospitalizations for malaria and other 
infections beyond 96 weeks [44]. Cotrimoxazole has also been shown to moderately reduce 
malaria incidence in HIV-exposed uninfected infants through age 2 years [45]; however, 
there have been no randomized clinical trials assessing the long-term impact of 
cotrimoxazole in HIV-exposed uninfected infants. Data from South Africa suggest that there 
is little benefit of cotrimoxazole prophylaxis for lower respiratory tract infections and a 
trend toward an increased risk of diarrhea without a decreased risk of lower respiratory tract 
infections in HIV-exposed uninfected infants receiving cotrimoxazole prophylaxis for more 
than 2 months while breastfeeding, but these findings were not statistically significant 
[46,47]. As countries continue to scale up prevention of mother-to-child HIV transmission 
(PMTCT) programs to reach goals for global elimination of new pediatric HIV infections, 
the need for data on cotrimoxazole use, and other preventive therapies in HIV-exposed, 
uninfected infants increases.
Although TB is one the most common causes of mortality in PLHIV, the difficulty of 
confirming a diagnosis of active TB in children remains a barrier to increasing case finding 
and ruling out active disease prior to IPT. Many promising advances have been made for TB 
diagnosis among PLHIV in the past 5 years, including the introduction of rapid, near point-
of-care diagnosis with the Xpert MTB/RIF assay [48]. Initial studies of Xpert MTB/RIF 
testing in children living with HIV show that diagnostic yield is up to a three times as high 
as smear microscopy of sputum, gastric aspirates, or nasopharyngeal aspirate specimens 
[48–53]. However, obtaining these specimens remains challenging in resource-limited 
settings, especially in the youngest children who are at highest risk of TB-related mortality. 
Novel approaches using stool and urine are being tested, but preliminary results have been 
mixed [49,54]. The difficulty of ruling out active TB in children with HIV in resource-
limited settings further complicates scale-up of IPT provision. In a routine clinical setting 
offering IPT to HIV-infected children in Kenya, less than half of all children enrolled in 
HIV care between 2008 and 2011 received IPT; the median time to IPT initiation was 8 
months due to the large burden of TB among HIV-infected children and the difficulty of 
excluding active TB disease in this setting [55]. Research on the impact of IPT on TB 
incidence and mortality has focused on adults; additional population-based studies in HIV-
exposed and HIV-infected infants and children are needed to strengthen the evidence base 
for this intervention [56,57]. The optimal duration, safety, efficacy, and cost–effectiveness 
of IPT alone or in addition to ART have not specifically been evaluated among children 
living with HIV, particularly in routine program settings in resource-limited settings. Further 
research is recommended for improving the accuracy and feasibility of diagnosis of active 
TB and other opportunistic infections, such as PCP and CMV, in HIV-infected children in 
resource-limited settings.
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Interventions to decrease the burden of common childhood illnesses will also help decrease 
morbidity and mortality among HIV-infected children. Increasing the coverage of routine 
childhood immunizations is one such essential intervention. Several studies have shown that 
the pneumococcal conjugate vaccine and the Haemophilus influenza conjugate vaccine may 
prevent a large proportion of HIV-associated and non-HIV-associated pneumonia in 
children [58–61]. In one study from South Africa, the overall reduction in invasive 
pneumococcal disease attributed to pneumococcal conjugate vaccination was 60 times 
higher in HIV-infected children compared with HIV-uninfected children [58,62]. Although 
limited data exist on the use of rotavirus vaccine in HIV-infected children, this vaccine has 
the potential to decrease the burden of acute gastroenteritis-related morbidity and mortality 
in high HIV prevalence regions [63–65].
Improving the health of families is also essential to improving outcomes for children. Data 
from multiple studies have shown that HIV-exposed and HIV-infected children are more 
likely to die when their mothers are ill or have died [66–68]. Importantly, data from South 
Africa show that mortality rates in children whose mothers received ART were not 
significantly different than HIV-unexposed children [68]. These data suggest that 
widespread implementation of universal ART for pregnant and breastfeeding women 
commonly referred to as (Option B+) may result in improved survival for children. 
Recognition and treatment of HIV infection and opportunistic infections in adults are also 
critical to the prevention of HIV infection and opportunistic infection-related morbidity in 
children, as these conditions tend to spread within families and households. HIV-infected 
women or HIV-infected family members who are co-infected with certain opportunistic 
pathogens are more likely to transmit these infections to their children, resulting in an 
increased likelihood of primary acquisition of such infections in the young child. For 
example, studies from Europe and Asia have shown that HIV-exposed infants have higher 
rates of congenital CMV infection than children born to mothers without HIV, and CMV is 
more common in HIV-infected infants than HIV-exposed uninfected infants [69,70]. 
Similarly, HIV-exposed infants are more likely to acquire hepatitis B and hepatitis C 
infection than HIV-unexposed infants [71–73]. Additional studies are needed to understand 
the prevalence and importance of perinatal transmission of CMV and hepatitis in sub-
Saharan Africa. Infection with Mycobacterium tuberculosis among infants and children 
primarily reflects acquisition from family members with active TB disease. Furthermore, 
maternal TB infection is associated with not only an increased risk of TB in the infant, but 
also an increased risk of HIV transmission, making TB prevention and treatment among 
pregnant women a critical intervention for improving HIV-free survival for children [74,75].
Health systems gaps
In order to improve access to pediatric HIV care and treatment in resource-limited settings, 
these services are increasingly being decentralized to district hospitals and primary 
healthcare settings. In these lower-level healthcare facilities, treatment options, human 
resources, and capacity for laboratory, radiologic, and pathologic diagnosis of opportunistic 
infections are more limited than at secondary or tertiary level health facilities [76]. Given 
these limitations, management decisions are often made on the basis of clinical presentation 
alone. However, clinical diagnoses are often incorrect, as highlighted by autopsy studies in 
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HIV-infected adults and children in sub-Saharan Africa, which show frequent discordance 
between clinical and postmortem diagnoses [36,77,78]. PCP and CMV pneumonia were 
identified as the main causes of mortality in autopsy studies of HIV-infected infants who 
died with presumptive bacterial pneumonia in Africa prior to the widespread availability of 
ART [77,79,80]. Additionally, these studies have identified lymphoid interstitial pneumonia 
(LIP) as one of the most common contributors to mortality [36]. LIP is commonly confused 
with TB, and the difficulty of confirming both of these diagnoses makes management 
difficult. Although corticosteroids are often available at a district hospital for children with 
LIP showing severe dyspnea, cyanosis, or hypoxia, this is often not the routine practice 
when the diagnosis is unclear or when clinicians are not experienced in managing clinical 
complications in children [81,82]. LIP has been shown to respond well to ART, but remains 
an important clinical consideration, especially in settings with low coverage of ART for 
HIV-infected children [83].
Identifying the various opportunistic infections in HIV-infected children requires a high 
index of suspicion from the healthcare worker, underscoring the need to ensure that clinical 
training emphasizes the importance of testing sick children for HIV and including 
opportunistic infections in the differential diagnosis of common childhood illnesses. 
Developing simplified algorithms for prevention, recognition, and treatment of opportunistic 
infections and other common illnesses in HIV-infected children will ensure that mid-level 
providers can deliver high quality pediatric HIV services. One proposed strategy involves 
including recommendations for diagnosis and management of opportunistic infections in 
Integrated Management of Childhood Illnesses (IMCI) guidelines along with treatment 
guidelines for common childhood illnesses such as diarrhea, pneumonia, and malaria and 
other interventions such as nutritional support, micronutrient supplementation, and 
deworming treatment [84,85]. However, data on the effectiveness of IMCI for early HIV 
diagnosis and for pediatric HIV management are limited; additional studies are needed to 
evaluate this approach [86,87].
Summary
There are clear regional differences in the incidence of HIV-associated opportunistic 
infections and opportunistic infection-associated mortality among children living with HIV 
globally. As PMTCT coverage increases, the number of annual pediatric HIV infections will 
continue to decrease, but continued expansion of HIV testing and treatment for children will 
remain critical for decreasing the impact of HIV until virtual elimination of mother-to-child 
HIV transmission becomes a global reality [12,88]. Implementation of family-centered and 
other innovative approaches to HIV testing and care is needed to help identify children 
living with HIV earlier and initiate ART earlier. Expanding coverage of ART for HIV-
infected children in resource-limited settings is the most critical intervention to reduce the 
impact of opportunistic infections. If the recently published WHO guidelines recommending 
universal treatment of HIV-infected children younger than 5 years and treatment of older 
children with CD4+ cell counts below 500 are adopted widely, treatment coverage for 
children living in resource-limited settings should dramatically increase.
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Adopting a universal treatment policy for the youngest children is likely to have the most 
impact in resource-limited settings in which access to CD4+ cell count testing or diagnostics 
for opportunistic infections are the most limited, in much the same way that Option B+ has 
expanded access to ART for pregnant women. However, even with ART, opportunistic 
infections and common childhood illnesses remain a major cause of morbidity and mortality 
for children with HIV. The limited attention to and capacity for diagnosis of pediatric 
opportunistic infections in resource-limited settings mean that the true burden of 
opportunistic infections in children living with HIV is unknown, especially in sub-Saharan 
Africa, where the majority of HIV-infected children live. These children are also more 
susceptible to common childhood illnesses, such as pneumonia and diarrhea, which are often 
more severe and fatal for HIV-infected children than uninfected children. Because many of 
these conditions have similar clinical presentations, healthcare workers relying on clinical 
symptoms alone may find it difficult to reliably distinguish opportunistic infections from 
common childhood illnesses.
Although guidelines for prevention, diagnosis, and management of opportunistic infections 
have been published in developed countries, these may not always be directly applicable to 
the management of disease in children living in resource-limited settings, highlighting the 
need to develop context-specific guidelines for opportunistic infection and healthcare 
worker training curricula. Further research is needed to identify the true burden of 
opportunistic infections, essential diagnostics, and treatment protocols for the routine 
package of care, especially in lower-level healthcare facilities in resource-limited settings. 
Ultimately, earlier diagnosis of HIV, earlier initiation of ART for all children, increased 
usage of evidence-based prophylactic regimens, and increased clinical suspicion for 
opportunistic infections are needed to improve the longterm health of children living with 
HIV.
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